Home › Burkitt Lymphoma › Vermont
Burkitt Lymphoma clinical trials in Vermont
3 studies for Burkitt Lymphoma are looking for participants at sites in Vermont.
Cities in Vermont
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Vermont and State Agricultural College, Burlington
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- University of Vermont and State Agricultural College, Burlington
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- University of Vermont and State Agricultural College, Burlington
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.